https://www.selleckchem.com/products/Cyt387.html
re reduced significantly from baseline (overall -6.6±6.07; smokers -5.17 + 6.96; non-smokers 8.06±4.44; all p0.0001). The mean difference between the two groups was 2.88 (p0.0001) at week 24. TFC was well tolerated. In this real world, multicentre study in India, TFC significantly improved lung function, symptoms and quality of life among all patients with COPD, but the effect was more pronounced among non-smoker COPD patients. In this real world, multicentre study in India, TFC significantly improved lung function, symptoms and
Like
Comment
Share
